Abnormal glycosylation of cell surface proteins takes place during which normal cells progress to a malignant neoplastic state. Our preliminary studies have demonstrated that selective dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) inhibitors have the promising therapeutic potential for certain solid cancers that require increased branching of N-linked glycans in their growth progressions. Selective DPAGT1 inhibitors are effective in killing a series of solid cancers in vitro, and displayed strong synergistic effects with FDA-approved anticancer drugs. We report scalable synthetic scheme for novel DPAGT1 inhibitors and detailed in vitro analyses of a selective DPAGT1 inhibitor, UT-17460 against pancreatic cancers.

N-glycosylation inhibitors towards novel anti-cancer chemotherapeutics

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.